Objective:

To elucidate the role of the ITGβ1-CLIC1 axis in OSCC progression and immune microenvironment modulation, highlighting its significance in cancer therapy.

Key Findings:

• ITGβ1 and CLIC1 are co-overexpressed in OSCC, correlating with poor prognosis, suggesting a potential biomarker for disease severity.
• The ITGβ1-CLIC1 axis drives tumor progression and alters immune infiltration patterns, indicating a mechanism for immune evasion.
• ITGβ1 mediates ECM remodeling and immune evasion in OSCC, highlighting its role as a therapeutic target.

Interpretation:

The findings suggest that targeting the ITGβ1-CLIC1 pathway may provide a novel therapeutic strategy for OSCC by disrupting tumor-immune interactions, potentially improving patient outcomes.

Limitations:

• The study relies on bioinformatic data which may not capture all biological complexities; further in vivo studies are needed to validate the therapeutic potential of targeting the ITGβ1-CLIC1 axis, particularly in diverse tumor microenvironments.

Conclusion:

The ITGβ1-CLIC1 pathway represents a promising target for therapeutic intervention in OSCC, potentially improving patient outcomes and offering new avenues for treatment.